Basel, Switzerland

Kenneth Atz

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: ETH Zurich, Hoffmann-La Roche Inc.. Active years: 2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenneth Atz. Retrieved from https://idiyas.com/inventor/kenneth-atz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kenneth Atz: Innovator in Cannabinoid Research

Introduction

Kenneth Atz is a distinguished inventor based in Basel, Switzerland, known for his significant contributions to cannabinoid research. With a keen focus on medicinal chemistry, Atz holds one patent that highlights his work in developing innovative compounds.

Latest Patents

Atz's notable patent is titled "Pyridine and Pyrazine Derivatives as Preferential Cannabinoid 2 Agonists." This invention relates to a compound of formula (I), which is defined in detail within the patent description and claims. The compound can be utilized as a medicament, showcasing its potential therapeutic applications, particularly in the cannabinoid domain.

Career Highlights

Throughout his career, Kenneth Atz has made significant strides in the pharmaceutical industry. He has worked with respected organizations such as Hoffmann-La Roche Inc., where he utilized his expertise in medicinal compounds, and the Eidgenössische Technische Hochschule Zürich, contributing to academic research and development.

Collaborations

Atz has collaborated with various professionals in his field, including notable coworkers like Simon Mensah Ametamey and Luca Claudio Gobbi. These collaborations have likely enriched his work, integrating diverse perspectives and expertise in cannabinoid research.

Conclusion

Kenneth Atz's innovative approach to developing cannabinoid-related compounds demonstrates his commitment to advancing medicinal research. With his patent and extensive professional background, Atz continues to be a significant figure in the field, contributing to the scientific community and improving potential treatments in medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…